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 Introduction 
 Around the millennium, anti-tumour necrosis factor 
(TNF)-α antibodies have been introduced into the thera-
py first to treat Crohn’s disease (CD)  [1–8] and later on 
to treat ulcerative colitis (UC)  [9–13] . They have signifi-
cantly changed the therapeutic landscape for inflamma-
tory bowel diseases (IBD) patients  [14, 15] .
 TNF has been shown to be one of the most pathophys-
iological relevant pro-inflammatory factors for the patho-
physiology of IBD  [16–20] . Neutralization of TNF has 
beneficial effects in a large number of patients  [15, 21, 22] . 
Nevertheless, there is a need for additional therapeutic 
options due to a non-negligible fraction of patients with 
primary non-response, loss of response or side-effects.
 As we have shown recently in the Swiss IBD Cohort 
Study, surgery is still frequent in CD patients and even 
after 30 years, up to 80% of the patients are likely to 
 undergo surgery  [23, 24] . The question is whether this 
trend changed significantly in the era of the anti-TNF an-
tibodies. A recent study presented by Jeuring et al.  [26] 
from the Netherlands on a Dutch population-based co-
hort study in the south Limburg area  [25] came to a 
 disappointing result. The disease behavior of CD patients 
 diagnosed in the biological era was not different to that 
diagnosed in the pre-biological era  [26] . CD patients 
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 Abstract 
 Cytokines are small proteins produced by a broad range of 
cells important in cell signaling. They include interleukins, 
but also chemokines, interferons, and tumor necrosis factors 
(TNF). They play an important role for communication be-
tween cells of the innate and adaptive immune system. The 
cytokine network is complex and, therefore, therapeutic in-
terventions are difficult. The first anti-cytokine strategy suc-
cessfully introduced into IBD therapy was the neutralization 
of TNF by antibodies. Beyond targeting this cytokine anti-
IL-23 strategies were demonstrated to be of therapeutic 
benefit in IBD. Anti-IL-6 strategies seem to have clinical po-
tential but also cause some risk for the patient due to the lack 
of CRP increase upon severe inflammation. JAK inhibitors 
target the intracellular signaling of several cytokine recep-
tors and represent a promising class of broader and some-
what unspecific anti-cytokine strategies. Many other anti-
cytokine approaches have failed due to the redundant na-
ture of the cytokine network. Whether further anti-cytokines 
strategies have potential for IBD treatment may be evaluat-
ed in future studies.  © 2017 S. Karger AG, Basel 
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 diagnosed in the pre-biological and biological era shared 
a similar risk of developing structuring or penetrating 
disease  [26] . These findings indicate that the disease 
 phenotype and the development of the disease phenotype 
have not changed significantly despite changes in the CD 
management.
 Data from the same cohort, on the other hand, showed 
that the number of surgeries done for just inflammatory 
complications has significantly decreased. This indicates 
that with anti-TNF antibodies we can successfully treat in-
flammation and all problems directly associated with in-
flammation. However, the processes finally leading to the 
penetrating and stricturing complications of the disease 
may be completely different. Perhaps these processes are 
not mainly mediated by TNF and may subsequently require 
different treatment options  [27, 28] . The disappointing fact 
is that bowel damage cannot be prevented with anti-TNF 
therapy and this clearly indicates a need for the develop-
ment of further therapies beyond current strategies.
 New Treatment Targets: Lessons from IBD 
Pathogenesis 
 We generally assume that there is an uncontrolled im-
mune reaction to endogenous and exogenous factors trig-
gered by genetic predisposition  [29–32] . A barrier defect 
is frequently seen as the first pathophysiological relevant 
problem  [33, 34] . This barrier defect may be caused by a 
reduction of phosphatidylcholine incorporation into the 
mucus layer of the mucosa  [35–37] . Stremmel et al. [37] 
have shown that the mucus layer in UC patients is de-
creased in thickness  [38] . This has stimulated new devel-
opments for a phosphatidylcholine substitution therapy 
as a new therapeutic approach in UC  [39–42] . So far, there 
is no biological therapy that can address this  problem.
 Among the known alterations in the barrier functions 
of IBD also are the differences with respect to defense in 
secretion as shown by the studies of Stange and Weh-
kamp [43--49] . The authors have attributed CD as being 
mainly a ‘defensin-deficiency’  [49] and in the case of ileal 
CD, it is referred to as  Paneth disease (with Paneth cells 
being the origin of  secreted α-defensin)  [50] . Defensins 
certainly play a role in the barrier function of the mucosa. 
The differences shown for IBD patients and controls are 
intriguing. However, it is unclear whether the differences 
in defensin expression and secretion are a primary defect 
or a secondary response to the presence of inflammation.
 In addition to the barrier defect in active IBD, there 
are endogenous and exogenous factors that may aggra-
vate the local inflammation such as food antigens, the 
intestinal microbiota or environmental factors such as 
nanoparticles or food additives  [51] . Those aggravating 
factors that act on an already present barrier defect may 
be more relevant in a genetically predisposed individual 
 [52–54] .
 Genetic susceptibility has been shown to occur in 
genes responsible for the barrier function and also in in-
nate immunity genes and in adaptive immunity genes 
 [52–54] . Endogenous and exogenous factors acting on a 
barrier defect and innate immune defect associated with 
a genetic pre-disposition lead to a deregulated immune 
response and finally to intestinal inflammation. This 
means that biological therapies that mainly focus on the 
deregulated immune response address their target at a 
relatively late stage in the pathophysiological cascade that 
finally leads to IBD.
 Nevertheless, cytokines are attractive targets for bio-
logical approaches in IBD therapy. Neurath  [55] has sum-
marized in a very nice overview article in Nature Reviews 
and Immunology in 2014 the cytokines that have been 
shown to be relevant in IBD. Important macrophage- 
derived cytokines are interleukin (IL)-12, IL-6, IL-23 and 
TNF. They act on the activation and regulation of the 
adaptive immune system, mainly T-cells. Important 
 T-cell derived cytokines are interferon-γ, IL-17, IL-22 
and also IL-6 and TNF  [55] . Th2 cell–derived cytokines 
are for example IL-5 and IL-13  [55] . Cytokines secreted 
by regulatory T-cells are for example IL-10 and trans-
forming growth factor β. Evidently, cytokines that are de-
rived from regulatory T-cells should not be antagonized, 
as they are anti-inflammatory by nature. In contrast, 
these cytokines may represent promising approaches for 
therapeutic substitution  [55] .
 The Promise of Precision Medicine 
 With the call for ‘precision medicine’, doctors try to 
promise that in course of time we will know which patient 
will benefit from which therapy  [56–58] . Indeed many of 
our IBD patients complain that they are subject to a 
 doctor-driven ‘try and error approach’. In a typical mod-
erate-to-severe IBD patient, we may first start with 
 immunosuppression and if this does not work within a 
few weeks or months, we take the next step towards ad-
ministering anti-TNF therapy. If anti-TNF therapy is not 
successful, we may use anti-integrin strategy. If this strat-
egy is also not successful, then we may take the next step 
of applying new anti-cytokines strategies.
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 Precision medicine promises now that each patient 
should benefit from the first therapy used after a respec-
tive diagnostic approach. It is claimed that DNA tests 
 taken before the onset of a therapy will identify the target 
population that benefits in all cases from a tailored ther-
apy  [57, 58] . This indeed is a nice promise. However, in 
IBD it seems to be rather unrealistic. It is more and more 
clear – as indicated by Rappaport  [59]  in recent paper in 
PLoS One – that genetic factors are not major causes of 
chronic diseases. Therefore, a simple genetic test will not 
identify the patients that benefit most from a specific 
therapy. In addition, the cytokine network is extremely 
complex  [60] . Recent manuscripts show that there are 
multiple backup mechanisms for every cytokine and in 
fact – at least for the time being – it is hard if not virtu-
ally impossible to predict which target in whom may be 
most promising  [61, 62] .
 The current pipeline in adult IBD therapy is rich in 
product developments. In 2013, we had the pleasure to 
write a review on new anti-cytokines for IBD ‘What is 
in  the pipeline?’  [63] . Unfortunately, 2/3 of the anti- 
cytokines strategies that were in the pipeline at that time 
have failed and are no longer followed. However, there 
are  several lines of development that currently seem to be 
quite promising.
 Anti IL-23 Strategies in IBD 
 Sandborn et al.  [64, 65] reported phase II trials of 
Ustekinumab in patients with moderate to severe CD. A 
total of 526 patients who had failed anti-TNF treatment 
were enrolled into the study to receive either placebo or 
Ustekinumab in a dosage of 1, 3 or 6 mg/kg i.v.  [64] . The 
prior endpoint of the study was the clinical response at 
week 6  [64] . One hundred thirty-one patients who re-
ceived placebo were compared to about the same number 
that received the different Ustekinumab preparations. 
With respect to the clinical response at week 6, there was 
a significant difference as compared to placebo for all 
concentrations used  [64] . The clinical response at week 8 
was highest for the 6 mg/kg dosage  [64] . Remission at 
week 6, however, showed no significant difference be-
tween the treatment groups and placebo. As Ustekinum-
ab has been approved as Stelara ® for the treatment for 
psoriasis, there was a small GETAID study published by 
Wils et al.  [66] from Lille about the efficacy and safety of 
subcutaneous Ustekinumab in refractory CD patients. 
This was a multicenter retrospective study on off-label 
use of Ustekinumab in patients with desperate situations 
 [66] . One hundred thirty-five patients were recruited. 
Thirteen patients were excluded, as the follow-up was 
less than 3 months. Finally, 122 were included in the 
analysis. Out of those 122  patients, 79 patients (64.7%) 
had a clinical benefit at 3 months  [66] . Forty-three pa-
tients had a clear non-response at 3 months. Out of the 
79 patients with a clinical benefit at 3 months, the major-
ity had luminal CD  [66] . Only a minority had perianal 
disease. However, out of 12 patients with perianal CD, 
8 showed a clinical benefit  [66] .
 Clinical response at week 6 was also the primary 
 endpoint in the phase 3 Uniti-2 trial that most likely will 
lead to the approval of Ustekinumab for CD  [67] . At 
6 weeks, the clinical response with placebo was 28%. In 
contrast, there was a clinical response of 51.7% with 
130 mg  subcutaneously and a clinical response of 55.5% 
in the 6 mg/kg i.v. group  [67] , keeping in mind that the 
6 mg/kg i.v. group also was the highest dosage group in 
the phase II trial that was reported earlier. After 8 weeks, 
the placebo response was 32%, the response with the sub-
cutaneous preparation was 47%, and with the i.v. prepara-
tion, it even increased to 58%  [67] . The subcutaneous 
preparation dosage that is used for psoriasis is 45 mg. 
Therefore, it appears that the dosage needed to be effective 
in IBD and CD is much higher as compared to psoriasis.
 Is this treatment strategy effective only for Ustekinum-
ab or are there other drugs that target the same cytokine? 
IL-23 is a heterodimer of 2 proteins. Ustekinumab is di-
rected against the p40 subunit in IL-23 that is also is pres-
ent in IL-12. The second protein subunit that is in con-
trast to p40 specific for IL-23 is the p19 unit. Targeting 
IL-12 has been shown not to be successful in IBD. There-
fore, it was considered that targeting the p19 subunit of 
IL-23 might be a more specific and promising approach. 
In a randomized double blind placebo controlled phase II 
induction study of MEDI2070, patients with active CD 
were dosed with anti-p19 antibody, if they had previous-
ly failed anti-TNF therapy. Sands et al. [68] have found 
that targeting anti-IL-23 might be successful in general 
and this is not restricted to anti-p40 antibodies. Targeting 
IL-23 alone and not IL-12 may offer a better benefit risk 
profile as compared with the dual inhibition of IL-12 and 
IL-23 by an anti-p40 antibody  [68] . When Sands et al. 
 [68] looked into the clinical efficacy in week 8 with the 
intention of treating population, they found that the dif-
ference with respect to CDA100 response between pla-
cebo and the  antibody was 22.5%. The placebo response 
was 26.7%, whereas the drug response was 49.2%. With 
respect to complete remission defined as a CD activity 
index (CDAI) below 150 at week 8, the placebo response 
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was 15% and the treatment response was 27.1%, thereby 
making up a difference of 12.2%, which was not statisti-
cally and significantly different with respect to composite 
endpoints  [68] . For the composite CDAI response, there 
was at week 8 a difference of 32.4%, which was highly sig-
nificant; the placebo composite response was 10%, where-
as the drug response was 42.4%  [68] . Also with respect to 
the CDAI remission composite, there was a difference of 
15.4%  [68] . The placebo response was 8.3% and the drug 
response was 23.7%. This indicates that in general 
 anti-IL-23 therapies provide a successful therapeutic 
strategy. We will in the near future see anti-IL-23 thera-
pies introduced into the treatment strategy for CD.
 Anti-IL-6 Therapy 
 The biology of IL-6 is even more as complex as the bi-
ology of anti-IL-12 or anti-IL-23. IL-6 binds to 2 proteins 
to induce responses of cells. It has a specific receptor. 
However, the IL-6 receptor will only induce signal trans-
duction when a second protein called gp130 is present 
according to the molecular weight. After binding of IL-6 
to the IL-6 receptor, a complex with 2 molecules of gp130 
is formed that finally mediates signal transduction  [69, 
70] . Cells that harbor only gp130 (which can also be a co-
receptor for other cytokine receptors) are not responsive 
to IL-6 (such as epithelial cells and smooth muscle cells) 
 [71–74] . On the other hand, hepatocytes and some leuko-
cytes express both proteins and respond well to the cyto-
kine  [71–74] .
 It needs to be emphasized that the expression of IL-6 
receptor in hepatocytes is essential for the formation of 
C-reactive protein (CRP). When IL-6 is neutralized, no 
stimulation of CRP production is found. There could 
even be severe inflammation; however, it is not indicated 
by increases in CRP.
 In 2004, in Gastroenterology, Ito et al. [75] reported a 
pilot trial of tocilizumab, an anti-IL-6 antibody, in CD 
patients. A total of 36 patients with a CDAI higher than 
150 were randomized to receive either placebo or alter-
nating infusions of 8 mg/kg tocilizumab and placebo ev-
ery 2 weeks or tocilizumab 8 mg/kg every 2 weeks  [75] . 
The response and remission rate were evaluated at week 
12. The tocilizumab infusion every 2 weeks showed a clin-
ical response in 75% of the patients  [75] . Clinical remis-
sion was seen only in the tocilizumab groups  [75] . This 
has stimulated a number of developments with different 
anti-IL-6 antibodies. A development by BMS has finally 
been stopped during the phase II trial, as a number of 
bowel perforations were observed. Unfortunately, those 
patients showed up in emergency situations, but the se-
verity of the complications was not realized because they 
did not develop sufficient CRP levels.
 Pfizer has supported the ANDANTE trial. Patients 
could have been previously treated with anti-TNF; they 
were supposed to have a CDI greater than 220 but less 
than 450 and CRP levels above 5 mg/l [76] . A colonoscopy 
had to confirm the ulcerations. The patients received 
3 dosings of the anti-IL-6 antibody or placebo. One group 
received 10 mg subcutaneously, one received 50 mg and 
one received 200 mg subcutaneously. The 200 mg group 
stopped receiving the anti-IL-6 antibody or placebo after 
observing bowel perforations in another trial, which was 
not part of the CD trial. The patients were followed up for 
28 weeks. The primary endpoint was a decrease of CDAI 
of 70 points or CDAI remission. At week 12, both groups 
were statistically significant for the 50 mg dose  [76] . There 
was a placebo response of 29.1% and a response of 38.3% 
with the 10 mg group (p = 0.19) and 47.6% with the 50 mg 
group (p = 0.045). With respect to CDAI remission, 11.5% 
achieved remission in the placebo group, 15% (p = 0.33) 
achieved remission in the 10 mg group and 28.5% (p = 
0.004) achieved remission in the 50 mg group. These re-
sults are quite encouraging [76]. However, at the moment 
it seems to be unclear whether the anti-IL-6 program will 
be maintained due to the risk of bowel perforation.
 JAK Inhibitors 
 Many cytokines signal to the cells via intracellular pro-
teins, the so-called Janus kinases or JAKs  [77] . There are 
mainly 3 JAKs and one similar protein called Tyk2 and 
they associate with different receptors. For example, the 
IL-6 receptor associates with JAK1, Tyk2 and JAK2. On 
the other hand, the IL-12 and IL-23 receptors associate 
with JAK2 and Tyk2 alone, whereas JAK1 does not play a 
role  [77] . For the IL-2 receptor, signaling via JAK1 and 
JAK3 has been shown. Different JAK inhibitors target dif-
ferent JAK proteins. Ruloxitinib, Lestaurtinib, Tofaci-
tinib and others target JAK1 and also JAK2. Tofacitinib 
also inhibits JAK3  [77] . For Tofacitinib, an inhibition of 
JAK 3 and less JAK1 and even less JAK2 have been shown.
 Tofacitinib has been tested in patients with UC  [78] . A 
total of 194 patients with active UC (Mayo score >6) re-
ceived either placebo or Tofacitinib in a dosage of 0.5, 3, 
10 or 15 mg twice daily  [78] . The primary endpoint in the 
study that was reported by Sandborn et al.  [78] in the New 
England Journal of Medicine in 2012 was the clinical re-
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
10
9 
- 1
/1
1/
20
18
 8
:3
4:
12
 A
M
 Anti-Cytokine Strategies beyond 
Anti-TNFα Therapy 
Dig Dis 2017;35:5–12
DOI: 10.1159/000449076
9
sponse with a decrease of the Mayo score of 3 points or 
30% at week 8. Tofacitinib at the dosage of 15 mg showed 
a significant effect with respect to clinical response. With 
respect to clinical remission, which was just 10% in the 
placebo patients but 33%, 48 or 41%, respectively, in the 
Tofacitinib groups 3, 10 and 15 mg of Tofacitinib showed 
significant effects  [78] . With respect to endoscopic re-
sponse, again the highest concentration was found to the 
most effective and it showed a significant result  [78] . For 
endoscopic remission, again all 3 higher concentrations 
were effective; however, it has to be kept in mind that in 
this phase 2 trial, numbers were still small.
 A larger trial now has confirmed the beneficial data for 
UC; however, in CD, the effect of Tofacitinib was not sta-
tistically significant (unpublished, presented at DDW 
2015). In contrast, Filgotinib, a selective JAK1 inhibitor 
that revealed to be effective in rheumatoid arthritis with 
a planned phase 3 program in this indication, was shown 
to be effective in a phase II study in patients with moder-
ate to severe CD  [79] . Filgotinib subsequently is the first 
JAK inhibitor to show efficacy in CD. The 48% clinical 
remission rate was statistically significant versus placebo 
after 10 weeks of induction therapy  [79] . The placebo re-
sponse was that only 23% of patients received a CDI low-
er than 150 points. Also, for the clinical response which 
was at a CDI decrease of 100 points or more, there was a 
difference between placebo (41%) as the Filgotinib 200 
mg group achieved a clinical response of 60% (p = 0.0386) 
[79]. There also was a significant improvement in clinical 
response as well as in the IBD quality-of-life question-
naire. The Filgotinib safety profile was similar to what 
has been described previously for other JAK inhibitors 
[79].
 Summary 
In this review, we outlined that the cytokine network 
is very complex and multiple backup mechanisms exist. 
This explains why many trials with biologicals that tar-
geted specific cytokines have failed in the past. How-
ever, 6 biologicals are currently approved for the treat-
ment of IBD: 4 anti-TNF agents (infliximab and bio-
similars, adalimumab, golimumab and certolizumab 
pegol) and 2 anti-integrin agents (natalizumab and ve-
dolizumab; natalizumab only in the United States and 
not in Europe) 
 Beyond anti-TNFs (and anti-integrins), IL-23 strate-
gies will soon be approved and will be available, especial-
ly for anti-TNF non-responders and refractory patients. 
Anti-IL-6 strategies do have clinical potential but also 
risks due to the lack of CRP increase and the reported 
bowel perforations. At the current moment, it remains 
doubtful whether additional drug-development pro-
grams of this therapeutic principal in IBD will be further 
advanced. JAK inhibitors target several cytokine recep-
tors and represent a promising class of broader and some-
what unspecific anti-cytokine strategies. They will also 
likely be soon available for the treatment of IBD patients 
(presumably with Tofacitinib as first-in-class available 
agent for UC).
 Whether further anti-cytokines strategies will have a 
potential for clinical practice will be elucidated in the 
 future.
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